Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | SLC6A2 | P23975 | 5/20 | 0.41 |
| ▸ | KDM4E | B2RXH2 | 2/20 | 0.40 |
| ▸ | MEN1 | O00255 | 1/20 | 0.40 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.40 |
| ▸ | NQO2 | P16083 | 1/20 | 0.40 |
| ▸ | FABP4 | P15090 | 2/20 | 0.40 |
| ▸ | HTR6 | P50406 | 1/20 | 0.39 |
| ▸ | GPR3 | P46089 | 1/20 | 0.38 |
| ▸ | ALKBH5 | Q6P6C2 | 1/20 | 0.37 |
| ▸ | FTO | Q9C0B1 | 1/20 | 0.37 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.37 |
| ▸ | SLC6A4 | P31645 | 2/20 | 0.36 |
| ▸ | MAPT | P10636 | 1/20 | 0.36 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.36 |
| ▸ | HDAC1 | Q13547 | 1/20 | 0.35 |
| ▸ | HDAC2 | Q92769 | 1/20 | 0.35 |
| ▸ | HDAC8 | Q9BY41 | 1/20 | 0.35 |
| ▸ | HDAC6 | Q9UBN7 | 1/20 | 0.35 |
| ▸ | HDAC9 | Q9UKV0 | 1/20 | 0.35 |
| ▸ | GPR84 | Q9NQS5 | 1/20 | 0.34 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL15171903 | 0.79 | SLC6A2 (0.38) | SLC6A2KDM4EMEN1KMT2ANQO2 | |
| SCHEMBL24186698 | 0.78 | SLC6A2 (0.40) | SLC6A2KDM4EMEN1KMT2ANQO2 | |
| SCHEMBL14584041 | 0.78 | GPR3 (0.37) | KDM4ENQO2GPR3CYP1A2GPR84 | |
| SCHEMBL26596971 | 0.78 | GPR3 (0.37) | KDM4EMEN1KMT2ANQO2HTR6 | |
| SCHEMBL14595047 | 0.78 | GPR3 (0.37) | KDM4EMEN1KMT2ANQO2HTR6 | |
| SCHEMBL24186697 | 0.77 | KMT2A (0.37) | SLC6A2KDM4EMEN1KMT2ANQO2 | |
| SCHEMBL13335097 | 0.76 | GPR84 (0.58) | HTR6GPR3CYP1A2SLC6A4GPR84 | |
| SCHEMBL29712382 | 0.76 | CYP1A2 (0.34) | KDM4ECYP1A2MAPTSMN1; SMN2 | |
| SCHEMBL29712360 | 0.76 | KDM4E (0.36) | KDM4EMEN1KMT2ACYP1A2MAPT | |
| SCHEMBL10234059 | 0.76 | BRD4 (0.43) | KDM4ENQO2CYP1A2SMN1; SMN2TSHR |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 30 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20230348434-A1 | NOVEL PYRIMIDINES AS EGFR-INHIBITORS AND METHODS OF TREATING DISORDERS | DANA-FARBER CANCER INSTITUTE, INC. | 2023-11-02 | — | — | US | disclosed |
| US-11673882-B2 | Pyrimidines as EGFR inhibitors and methods of treating disorders | DANA-FARBER CANCER INSTITUTE, INC. (US) | 2023-06-13 | — | — | US | disclosed |
| US-20230008433-A1 | Inhibitors of SARM1 | DISARM THERAPEUTICS, INC. | 2023-01-12 | — | — | US | disclosed |
| CN-114835622-A | N-tert-butyl protection-3-substituted indole compound and preparation method thereof | 常州大学 | 2022-08-02 | — | — | CN | disclosed |
| US-20220127265-A1 | THERAPEUTIC COMPOUNDS AND USES THEREOF | GENENTECH, INC. (US) | 2022-04-28 | — | — | US | disclosed |
| US-11247989-B2 | Therapeutic compounds and uses thereof | GENENTECH, INC. (US) | 2022-02-15 | — | — | US | disclosed |
| US-11229708-B2 | Conjugates of quaternized tubulysin compounds | SEAGEN INC. (US) | 2022-01-25 | — | — | US | disclosed |
| CN-107108512-B | Therapeutic compounds and uses thereof | 基因泰克公司 | 2021-05-04 | — | — | CN | disclosed |
| US-10870636-B2 | Pyrimidines as EGFR inhibitors and methods of treating disorders | DANA-FARBER CANCER INSTITUTE, INC. (US) | 2020-12-22 | — | — | US | disclosed |
| EP-3204360-B1 | THERAPEUTIC COMPOUNDS AND USES THEREOF | GENENTECH INC (US) | 2020-08-26 | — | — | EP | disclosed |
| WO-2016055028-A1 | THERAPEUTIC COMPOUNDS AND USES THEREOF | GENENTECH, INC. (US) | 2016-04-14 | — | — | WO | disclosed |
| WO-2016055028-A1 | THERAPEUTIC COMPOUNDS AND USES THEREOF | GENENTECH, INC. (US) | 2016-04-14 | — | — | WO | disclosed |
| US-20150210700-A1 | INDOLE-SUBSTITUTED PYRROLOPYRIMIDINYL INHIBITORS OF UBA6 | TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) | 2015-07-30 | — | — | US | disclosed |
| US-9000220-B2 | Organophosphorus compounds based on tetraphenol (TP)-substituted structures | EVONIK DEGUSSA GMBH (DE) | 2015-04-07 | — | — | US | disclosed |
| US-8329718-B2 | N-linked heterocyclic antagonists of P2Y1 receptor useful in the treatment of thrombotic conditions | BRISTOL-MYERS SQUIBB COMPANY (US) | 2012-12-11 | — | — | US | disclosed |
| US-20120197025-A1 | ORGANOPHOSPHORUS COMPOUNDS BASED ON TETRAPHENOL (TP)-SUBSTITUTED STRUCTURES | EVONIK OXENO GMBH (DE) | 2012-08-02 | — | — | US | disclosed |
| US-20100197716-A1 | N-LINKED HETEROCYCLIC ANTAGONISTS OF P2Y1 RECEPTOR USEFUL IN THE TREATMENT OF THROMBOTIC CONDITIONS | BRISTOL-MYERS SQUIBB COMPANY | 2010-08-05 | — | — | US | disclosed |
| US-7728008-B2 | N-linked heterocyclic antagonists of P2Y1 receptor useful in the treatment of thrombotic conditions | BRISTOL-MYERS SQUIBB COMPANY (US) | 2010-06-01 | — | — | US | disclosed |
| US-7728008-B2 | N-linked heterocyclic antagonists of P2Y1 receptor useful in the treatment of thrombotic conditions | BRISTOL-MYERS SQUIBB COMPANY (US) | 2010-06-01 | — | — | US | disclosed |
| US-7550499-B2 | Urea antagonists of P2Y1 receptor useful in the treatment of thrombotic conditions | BRISTOL-MYERS SQUIBB COMPANY (US) | 2009-06-23 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (10 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20230348434-A1 | NOVEL PYRIMIDINES AS EGFR-INHIBITORS AND METHODS OF TREATING DISORDERS | EGFR, ERBB2, ERBB3 | SLC6A2 3472/4885KDM4E 4477/4885MEN1 4385/4885 |
| US-11247989-B2 | Therapeutic compounds and uses thereof | EP300, HDAC1, CREBBP | SLC6A2 3840/4885KDM4E 358/4885MEN1 1542/4885 |
| US-11673882-B2 | Pyrimidines as EGFR inhibitors and methods of treating disorders | EGFR, ERBB2, ERBB3 | SLC6A2 3037/4885KDM4E 4498/4885MEN1 4300/4885 |
| US-20230008433-A1 | Inhibitors of SARM1 | SARM1, SMN1; SMN2, SARNP | SLC6A2 2958/4885KDM4E 3087/4885MEN1 4363/4885 |
| US-10870636-B2 | Pyrimidines as EGFR inhibitors and methods of treating disorders | EGFR, ERBB2, ERBB3 | SLC6A2 3037/4885KDM4E 4498/4885MEN1 4300/4885 |
| US-20100197716-A1 | N-LINKED HETEROCYCLIC ANTAGONISTS OF P2Y1 RECEPTOR USEFUL IN THE TREATMENT OF THROMBOTIC CONDITIONS | P2RY1, P2RY11, P2RY13 | SLC6A2 660/4885KDM4E 4734/4885MEN1 1706/4885 |
| US-11229708-B2 | Conjugates of quaternized tubulysin compounds | LCK, UACA, TEKT1 | SLC6A2 765/4885KDM4E 2538/4885MEN1 126/4885 |
| US-20120197025-A1 | ORGANOPHOSPHORUS COMPOUNDS BASED ON TETRAPHENOL (TP)-SUBSTITUTED STRUCTURES | PTMS, HPD, INPPL1 | SLC6A2 1424/4885KDM4E 2374/4885MEN1 1363/4885 |
| US-20150210700-A1 | INDOLE-SUBSTITUTED PYRROLOPYRIMIDINYL INHIBITORS OF UBA6 | UBA6, UBE2V1, UBA1 | SLC6A2 1803/4885KDM4E 913/4885MEN1 2856/4885 |
| US-20220127265-A1 | THERAPEUTIC COMPOUNDS AND USES THEREOF | EP300, HDAC1, CREBBP | SLC6A2 3840/4885KDM4E 358/4885MEN1 1542/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.